Drug Information Association Logo
« Back to Listing

Collaboration in R&D: What’s New for TransCelerate BioPharma?

Track:
Clinical Operations

Day & Time:
June 17, 8:00AM - 9:30AM (Pacific Standard Time)

Session Number:
202

Room Number:
2

Level:
Intermediate

Type:
Forum

Title:
Collaboration in R&D: What’s New for TransCelerate BioPharma?

Chair(s):
Susan Cantrell
Senior Vice President and Managing Director, DIA Americas
DIA, United States

Description:
This forum will provide highlights and accomplishments from the original five TransCelerate initiatives – development of a standardized approach for risk-based site monitoring, mutual recognition of clinical trial site qualification and training, development of clinical data standards, establishment of a comparator drug network and development of a shared investigator site portal, as well as discuss current progress of new initiatives and line extensions in 2014, including creation of common clinical trial protocol templates, development of a special populations (pediatric and minority) clinical trial network and establishment of a shared investigator registry. There will also be Q&A with the panel, which will include members of TransCelerate’s Board of Directors and Operations Committee.

Learning Objective(s):
Discuss accomplishments to date for the TransCelerate initiatives; Describe the progress of new initiatives and line extensions in 2014.

Presentation(s) & Speaker(s):
Panelist
Dalvir Gill, PhD
Chief Executive Officer
TransCelerate Biopharma Inc, United States

Panelist
John W Hubbard, PhD
Senior Vice President and Worldwide Head of Development Operations
Pfizer Inc, United States

Panelist
Lynn G. Marks, MD
Senior Vice President, Projects, Clinical Platforms and Sciences
Glaxosmithkline, United States